TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06799520
Drug: VIS171
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS171 will be administered as a SC injection.
Study: NCT06418711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
Study: NCT06236061
Drug: LCZ/AML 200 mg/2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ/AML 200 mg/2.5 mg
Study: NCT06236061
Drug: LCZ/AML 200 mg/5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ/AML 200 mg/5 mg
Study: NCT06236061
Drug: LCZ/AML 200 mg/10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ/AML 200 mg/10 mg
Study: NCT06239272
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
Study: NCT06580002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06388941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally
Study: NCT05763199
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will be administered per standard of care.
Study: NCT05151471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06075095
Drug: BGF MDI HFO 320/14.4/9.6μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
Study: NCT06075095
Drug: BGF MDI HFA 320/14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
Study: NCT05573464
Drug: BGF MDI HFO 320/14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Study: NCT06527404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Injection
Study: NCT05762952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules formulated by pharmacy to be indistinguishable from active drug
Study: NCT04906408
Drug: Traditional
Normalized name: Midol Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisions will be dressed with bacitracin/xeroform
Study: NCT05064085
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
Study: NCT05923424
Drug: REGN17092
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
Study: NCT05923424
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending IV or SC administration per the protocol
Study: NCT04447989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextrose 5%
Study: NCT05972629
Drug: SAR444836
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump, intravenous infusion (IV)
Study: NCT06343805
Drug: AJ1-11095
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type II JAK2 Inhibitor
Study: NCT04948333
Drug: ABL001 40mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of 40 mg will be taken orally twice a day (BID)
Study: NCT04948333
Drug: ABL001 200mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five tablets of 40 mg will be taken orally once a day (QD)
Study: NCT06410599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
Study: NCT05528224
Drug: conventional medical treatment (TAU)
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
Study: NCT05728671
Drug: IP2015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT05624450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of matching placebo on Day 1.
Study: NCT05819138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide placebo injection
Study: NCT06676579
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
Study: NCT06118580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape-flavored drink
Study: NCT06193486
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
Study: NCT05133804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Reboxetine
Study: NCT05133804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Ritalin
Study: NCT05531656
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT05531656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active study drug
Study: NCT02004782
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
Study: NCT02004782
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
Study: NCT05209165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo and intake visit for VA MOVE
Study: NCT04804033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo softgel capsule.
Study: NCT05370599
Drug: Anti-hypertensive agent: Chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Study: NCT05097989
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05097989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02497638
Drug: Placebo (corresponding to atorvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet (corresponding to atorvastatin) once daily until progression.
Study: NCT05282446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablet
Study: NCT05536141
Drug: casdatifan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06145191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic topical application (1x) of placebo (0.9% NaCl, 2ml, room temperature) applied before sampling
Study: NCT06406777
Drug: 129Xe MRI scans
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
Study: NCT05537025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
Study: NCT06429722
Drug: NMRA-335140 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
Study: NCT06429722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT06654037
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06608927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06603662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to the Control group will receive oral placebo once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours.
Study: NCT06671834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution of placebo
Study: NCT06616766
Drug: YH42946
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH42946
Study: NCT06600178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet given to subject vs. active drug.
Study: NCT06626139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants will receive an inactive placebo.
Study: NCT06693323
Drug: AHCC®capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06696820
Drug: PCSK9 inhibitors combined with atorvastatin/rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous injection of 420 mg Iroceliumab upon admission, along with a standard dose of 20 mg Atorvastatin or 10 mg Rosuvastatin
Study: NCT06696820
Drug: Atorvastatin/Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Atorvastatin 20 mg / Rosuvastatin 10 mg
Study: NCT04745689
Drug: AZD2811
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions through maintenance phase until PD or other discontinuation criteria.
Study: NCT06698575
Drug: ABI-1179
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
Study: NCT06698575
Drug: ABI-1179 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
Study: NCT06435156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT06685887
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
Study: NCT06742762
Drug: AZD5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT06174909
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
Study: NCT06795399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-131461 matched placebo will be administered as oral tablets.
Study: NCT06174909
Drug: Triple Antibiotic paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
Study: NCT05351671
Drug: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
Study: NCT05351671
Drug: Placebo (saline dosed every 8 hours for a total of 3 doses)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
Study: NCT06619626
Drug: group without alveolar recruitment strategy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect on mechanical parameters of patients without alveolar recruitment strategy
Study: NCT04990427
Drug: CLBS201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
Study: NCT05968118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
Study: NCT05173441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
Study: NCT05605093
Drug: Shionogi Protease Inhibitor (S-217622)
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
Study: NCT05605093
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
Study: NCT06641466
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral disintegrating tablets for 7 days
Study: NCT06641466
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for acute treatment as needed
Study: NCT04837924
Drug: paracetamol 1 gram IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 1 gram IV every six hours, 4 times in 24 hours
Study: NCT05555823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablets for oral intake
Study: NCT05555823
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsules for oral intake
Study: NCT05842044
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
Study: NCT05842044
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
Study: NCT05842044
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
Study: NCT04234971
Drug: Intervention group (DBM/BMP)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
Study: NCT04234971
Drug: Control group(autologous ICBG)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
Study: NCT05840679
Drug: Irrigation Solution
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different concentrations of NaOCl are being used as the endodontic irrigant.
Study: NCT06029439
Drug: NMRA-335140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
Study: NCT06158841
Drug: Etentamig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06474208
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
Study: NCT06474208
Drug: Formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
Study: NCT06474208
Drug: Formulation 5 (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of formulation 1 in SD.
Study: NCT06468228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05891171
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as specified in the treatment arm
Study: NCT05891171
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as specified in the treatment arm
Study: NCT05114278
Drug: oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive an oral iron supplementation (100mg/day).
Study: NCT05705076
Drug: catheter induced thromboprophylaxis
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulation for catheter induced thromboprophylaxis
Study: NCT01368315
Drug: CT327 application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
Study: NCT01368315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
Study: NCT01368315
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention to one out of four test fields marked on the patient's back.
Study: NCT05964413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Infusion
Study: NCT05108805
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05630781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator taken for \~10 days
Study: NCT05933057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
Study: NCT05512130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
Study: NCT06082557
Drug: T60c injection
Normalized name: SUCTION CATHETER,14FR ALLEGIANCE #T60C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion.